Thomas John Baranski, MD, PhD
- Washington University Transgender Center
Sees Patients For
Endocrinology, metabolism, diabetes.
Patients Seen At
- Center for Advanced Medicine Medicine Multispecialty Center4921 Parkview PlaceSt. Louis, MO 63110Suite: CFloor: 5Fax: 314-747-3065Appointments:
- Barnes-Jewish Hospital
- Endocrinology, Diabetes and Metabolism
- Internal Medicine
Academic Title(s)Associate Professor, Medicine
Division of Endocrinology, Diabetes and Metabolism
Assistant Professor, Molecular Biology and Pharmacology
1998 Diabetes, Endocrinology and Metabolism, University of California, San Francisco, CaliforniaResidency
1994 University of California, San Francisco, CaliforniaPh.D.
1992 Washington University School of MedicineMedical Degree
1992 Washington University School of Medicine, St. Louis, MissouriB.S.
1985 University of Wisconsin, Madison, Wisconsin
Publications & Research
Disclosure of Financial Interests with Industry
Washington University and its physicians and health professionals are committed to ensuring integrity and objectivity in medical decision-making. Some of our physicians and health professionals work collaboratively with pharmaceutical, medical device or other medical care related companies to develop innovative ideas and products that can improve health care delivery and clinical outcomes for patients. In some instances, our physicians and health professionals have an ownership or potential ownership interest in a commercial company; and/or are paid by a commercial company to provide advice on product design or to speak about the use of medications, devices, equipment or procedures. These payments may include: a) compensation for consulting and speaking engagements, b) equity, and/or c) royalties for products invented by our faculty. Any payments to Washington University physicians or health professionals must be based on tangible services and may not exceed fair market value for their work. In addition to disclosure on this website, physicians and health professionals earning more than $10,000 per year must disclose their corporate financial relationship in writing to patients when prescribing or using that company's products.